Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03106077
Recruitment Status : Recruiting
First Posted : April 10, 2017
Last Update Posted : November 14, 2018
National Comprehensive Cancer Network
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

The goal of this clinical research study is to learn if mirvetuximab soravtansine can help to control either newly diagnosed or metastatic (has spread) triple-negative breast cancer (TNBC).

Mirvetuximab soravtansine is designed to stop cell growth by blocking certain proteins in the cancer cells related to the mineral folate. This is believed to cause the cancer cells to die.

Condition or disease Intervention/treatment Phase
Malignant Neoplasm of Breast Drug: Mirvetuximab Soravtansine Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC
Actual Study Start Date : June 5, 2017
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Metastatic Triple-Negative Breast Cancer (TNBC)

Participants receive Mirvetuximab Soravtansine once every 3 weeks.

Participants treated until disease progression, therapy intolerance or withdrawal of informed consent.

Drug: Mirvetuximab Soravtansine
6 mg/kg by vein, once every 3 weeks.
Other Name: IMGN853

Experimental: Newly Diagnosed Triple-Negative Breast Cancer (TNBC)

Participants receive Mirvetuximab Soravtansine once every 3 weeks.

Participants receive a maximum of 4 cycles of therapy prior to undergoing surgical resection. Patients allowed to discontinue therapy for intolerance, disease progression or withdrawal of consent.

Drug: Mirvetuximab Soravtansine
6 mg/kg by vein, once every 3 weeks.
Other Name: IMGN853

Experimental: Metastatic Run-In Cohort
14 participants recruited in the first stage to receive Mirvetuximab Soravtansine once every 3 weeks.
Drug: Mirvetuximab Soravtansine
6 mg/kg by vein, once every 3 weeks.
Other Name: IMGN853

Primary Outcome Measures :
  1. Response Rate of Mirvetuximab Soravtansine in Participants with Metastatic FRa+ Triple-Negative Breast Cancer (TNBC) [ Time Frame: 6 months ]
    Response defined as confirmed complete response (CR) or partial response (PR) per RECIST.

  2. Pathologic Response of Mirvetuximab Soravtansine in Participants Chemotherapy Insensitive, FRa+ Triple-Negative Breast Cancer (TNBC) [ Time Frame: 12 weeks ]
    Pathologic Response measured by Residual Cancer Burden (RCB) as pathologic compete response (pCR/RCB-0) or minimal residual disease (MRD/RCB-I).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age =/> 18 years.
  2. ECOG performance status of 0 or 1.
  3. Confirmed invasive triple-negative breast cancer defined as ER<10%; PR<10% by IHC and HER2 0-1+ by IHC or 2+, FISH < 2, gene copy number < 4.
  4. (For Cohort A) - Archived tissue available at pre-screening to confirm FR alpha+ breast cancer.
  5. (For Cohort A) Archived tissue available pre-screening to confirm FR alpha+ breast cancer. (For Cohort B) Confirmed FRalpha+ breast cancer defined as high FRalpha expression: =/>75% of cells having =/>1+ expression, or moderate FRalpha expression: 25%-74% of cells with =/>1+ expression.
  6. (For Cohort A) Measurable disease per RECIST. (For cohort B) Clinical or radiologic primary tumor size of at least 1.5cm prior to enrollment onto protocol 2014-0185 (ARTEMIS). Primary tumor of at least 1.0 cm or evidence of continued lymphnode involement by imaging (ultrasound or MRI) after Adriamycin-based neoadjuvant therapy.
  7. (For cohort B): primary tumor sample collected before NACT started (on ARTEMIS) and underwent molecular testing for integral biomarkers including immunohistochemical assessment of FRalpha.
  8. (For cohort A): no limit on prior therapies for metastatic disease. (Relapse of disease within 6 months of adjuvant or neoadjuvant chemotherapy is considered 1 line of therapy for metastatic disease). (For cohort B): received at least one dose of an anthracycline-based NACT. Patients are eligible if therapy was discontinued due to disease progression or therapy intolerance. Patients with disease progression on anthracycline-based therapy should be evaluated by the surgical team. If the patient is deemed inoperable at the time of evaluation, the patient may continue to undergo protocol therapy with a goal of reduction in tumor size to become operable. If the patient is deemed at high risk of becoming inoperable by the surgical team based upon tumor size or location, the patient will be considered ineligible for study and will be recommended to go to surgery.
  9. (For cohort B): Primary tumor size of at least 1.0 cm by imaging (ultrasound or MRI) or evidence of continued lymph node involovement by imaging (ultrasound or MRI) after Adriamycin-based neoadjuvant therapy.
  10. (For cohort B): baseline MUGA or echocardiogram showing LVEF =/> 50% within 6 weeks prior to initiation of NACT.
  11. (For both cohorts A and B): Adequate bone marrow function as shown by: • ANC =/>1.5x10^9 /L, • Platelets =/ >100x10^9 /L, • Hb >9 G/dL.
  12. (For both cohorts A and B): Adequate organ function as shown by: • Total serum bilirubin =/<2.0 mg/dL, • ALT and AST =/<2.5x ULN (=/<5x ULN in patients with liver metastases), • INR =/<2; • Serum creatinine =/<1.5x ULN; • Serum albumin >2.
  13. Signed informed consent obtained prior to any screening procedures.
  14. (For cohort A only): Time from prior therapy: a. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. b. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
  15. (For cohort B only): patients must have at least 3 and no more than 5 weeks between anthracycline-based therapy and start of treatment with mirvetuximab soravtansine.
  16. (For both cohorts A and B): Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia).
  17. (For both cohorts A and B): WCBP must have a negative pregnancy test within 3 days prior to the first dose of study treatment.

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
  3. (For Cohort B only): presence of metastatic disease or prior radiation therapy of the primary breast carcinoma or axillary lymph nodes.
  4. Women of child-bearing potential (WCBP), defined as all women capable of becoming pregnant, won't use highly effective methods of contraception during the study and 12 weeks after. Highly effective contraception methods include combination of any two of the following: • Placement of an IUD or IUS; • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository; • Total abstinence or; • Male/female sterilization. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile, or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to study entry. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential.
  5. Male patients whose sexual partner(s) are WCBP who are not willing to use adequate contraception, during the study and for 12 weeks after the end of treatment.
  6. Patients with > Grade 1 peripheral neuropathy.
  7. Active or chronic corneal disorder, including but not limited to the following: Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and acquired monocular vision.
  8. Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following: • Known active hepatitis B or C • Known Human Immunodeficiency Virus (HIV) infection • Varicella-zoster virus (shingles) • Cytomegalovirus infection • Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment
  9. Clinically- significant cardiac disease: • Recent myocardial infarction (=/<6 months prior to day 1), • Unstable angina pectoris, • Uncontrolled congestive heart failure (New York Heart Association > class II), • Uncontrolled hypertension (=/> CTCAE v4.03 Grade 3), • Prior history of hypertensive crisis or hypertensive encephalopathy, • Uncontrolled cardiac arrhythmias, • Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), • Severe aortic stenosis, • Clinically significant peripheral vascular disease, • =/> Grade 3 cardiac toxicity following prior chemotherapy • QTc >470 for females and >450 for males
  10. History of neurological conditions that would confound assessment of treatment-emergent neuropathy.
  11. History of hemorrhagic or ischemic stroke within the last 6 months
  12. History of cirrhotic liver disease
  13. Previous clinical diagnosis of non-infectious pneumonitis or non-infectious interstitial lung disease.
  14. Prior hypersensitivity to monoclonal antibodies.
  15. Patients who have a history of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for =/>3 years
  16. Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis. Patients with previously treated CNS metastasis (excluding carcinomatous meningitis) may participate if they are stable (without evidence of progression by imaging, using identical imaging modality at each assessment, for at least 4 weeks prior to first dose of study treatment), have no evidence of new or emerging CNS metastasis, and are not using steroids for at least 7 days prior to first dose of study treatment.
  17. History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment
  18. Required used of folate-containing supplements (e.g. folate deficiency)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03106077

Contact: Stacy Moulder, MD 713-563-0730

United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Comprehensive Cancer Network
Principal Investigator: Stacy Moulder, MD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT03106077     History of Changes
Other Study ID Numbers: 2016-0683
NCI-2018-01213 ( Registry Identifier: NCI CTRP )
First Posted: April 10, 2017    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by M.D. Anderson Cancer Center:
Malignant neoplasm of breast
Triple-Negative Breast Cancer
Metastatic Triple-Negative Breast Cancer
Newly Diagnosed Triple-Negative Breast Cancer
Mirvetuximab Soravtansine

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs